UroGen reports record Q2 JELMYTO revenue of $21.1M, positive Phase 3 data for UGN-102

UroGen Pharma Ltd.

Q2 2023 JELMYTO net revenue $21.1M (+27% YoY); net loss $24.1M ($1.03/share) vs $26.7M ($1.18) year ago.
ENVISION Phase 3 trial met primary endpoint: 79.2% complete response at 3 months in LG-IR-NMIBC patients.
ATLAS Phase 3 showed 55% reduction in recurrence/progression/death risk for UGN-102+TURBT vs TURBT alone.
Completed $120M private placement of ordinary shares and pre-funded warrants to support UGN-102 launch.
Cash and equivalents $55.3M at June 30, 2023, excluding $120M proceeds; FY revenue guidance $76-86M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

UroGen Pharma Ltd. reported the second quarter ended June 30, 2023 results: revenue $21.1 million.

Period: the second quarter ended June 30, 2023
Revenue: $21.1 million
Result: reported results

Exact text from the filing

UroGen reported net product revenue of JELMYTO for the second quarter 2023 of $21.1 million, compared to $16.6 million in the second quarter of 2022.

View on SEC.gov

Browse all earnings releases →

UroGen Pharma Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-23-208139

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.